First Time Loading...

Immatics NV
NASDAQ:IMTX

Watchlist Manager
Immatics NV Logo
Immatics NV
NASDAQ:IMTX
Watchlist
Price: 10.15 USD -1.07% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

IMTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. [ Read More ]

The intrinsic value of one IMTX stock under the Base Case scenario is 5.74 USD. Compared to the current market price of 10.15 USD, Immatics NV is Overvalued by 43%.

Key Points:
IMTX Intrinsic Value
Base Case
5.74 USD
Overvaluation 43%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Immatics NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling IMTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Immatics NV

Provide an overview of the primary business activities
of Immatics NV.

What unique competitive advantages
does Immatics NV hold over its rivals?

What risks and challenges
does Immatics NV face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Immatics NV.

Provide P/S
for Immatics NV.

Provide P/E
for Immatics NV.

Provide P/OCF
for Immatics NV.

Provide P/FCFE
for Immatics NV.

Provide P/B
for Immatics NV.

Provide EV/S
for Immatics NV.

Provide EV/GP
for Immatics NV.

Provide EV/EBITDA
for Immatics NV.

Provide EV/EBIT
for Immatics NV.

Provide EV/OCF
for Immatics NV.

Provide EV/FCFF
for Immatics NV.

Provide EV/IC
for Immatics NV.

Show me price targets
for Immatics NV made by professional analysts.

What are the Revenue projections
for Immatics NV?

How accurate were the past Revenue estimates
for Immatics NV?

What are the Net Income projections
for Immatics NV?

How accurate were the past Net Income estimates
for Immatics NV?

What are the EPS projections
for Immatics NV?

How accurate were the past EPS estimates
for Immatics NV?

What are the EBIT projections
for Immatics NV?

How accurate were the past EBIT estimates
for Immatics NV?

Compare the revenue forecasts
for Immatics NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Immatics NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Immatics NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Immatics NV compared to its peers.

Compare the P/E ratios
of Immatics NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Immatics NV with its peers.

Analyze the financial leverage
of Immatics NV compared to its main competitors.

Show all profitability ratios
for Immatics NV.

Provide ROE
for Immatics NV.

Provide ROA
for Immatics NV.

Provide ROIC
for Immatics NV.

Provide ROCE
for Immatics NV.

Provide Gross Margin
for Immatics NV.

Provide Operating Margin
for Immatics NV.

Provide Net Margin
for Immatics NV.

Provide FCF Margin
for Immatics NV.

Show all solvency ratios
for Immatics NV.

Provide D/E Ratio
for Immatics NV.

Provide D/A Ratio
for Immatics NV.

Provide Interest Coverage Ratio
for Immatics NV.

Provide Altman Z-Score Ratio
for Immatics NV.

Provide Quick Ratio
for Immatics NV.

Provide Current Ratio
for Immatics NV.

Provide Cash Ratio
for Immatics NV.

What is the historical Revenue growth
over the last 5 years for Immatics NV?

What is the historical Net Income growth
over the last 5 years for Immatics NV?

What is the current Free Cash Flow
of Immatics NV?

Financials

Balance Sheet Decomposition
Immatics NV

Current Assets 449.4m
Cash & Short-Term Investments 425.9m
Receivables 5.7m
Other Current Assets 17.7m
Non-Current Assets 60.6m
PP&E 57.1m
Intangibles 1.5m
Other Non-Current Assets 2m
Current Liabilities 156.6m
Accounts Payable 25.2m
Accrued Liabilities 4.8m
Other Current Liabilities 126.5m
Non-Current Liabilities 128.3m
Long-Term Debt 12.8m
Other Non-Current Liabilities 115.5m
Efficiency

Earnings Waterfall
Immatics NV

Revenue
54m EUR
Operating Expenses
-155.7m EUR
Operating Income
-101.7m EUR
Other Expenses
4.7m EUR
Net Income
-97m EUR

Free Cash Flow Analysis
Immatics NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

IMTX Profitability Score
Profitability Due Diligence

Immatics NV's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

ROE is Increasing
Positive 3-Years Revenue Growth
Negative Revenue Growth Forecast
Negative 1-Year Revenue Growth
19/100
Profitability
Score

Immatics NV's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

IMTX Solvency Score
Solvency Due Diligence

Immatics NV's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
48/100
Solvency
Score

Immatics NV's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMTX Price Targets Summary
Immatics NV

Wall Street analysts forecast IMTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMTX is 19.09 USD with a low forecast of 14.14 USD and a high forecast of 26.25 USD.

Lowest
Price Target
14.14 USD
39% Upside
Average
Price Target
19.09 USD
88% Upside
Highest
Price Target
26.25 USD
159% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

IMTX Price
Immatics NV

1M 1M
-13%
6M 6M
+16%
1Y 1Y
+41%
3Y 3Y
-16%
5Y 5Y
-33%
10Y 10Y
-33%
Annual Price Range
10.15
52w Low
6.6
52w High
12.94
Price Metrics
Average Annual Return -14.47%
Standard Deviation of Annual Returns 27.28%
Max Drawdown -62%
Shares Statistics
Market Capitalization 1B USD
Shares Outstanding 102 990 000
Percentage of Shares Shorted 10.94%

IMTX Return Decomposition
Main factors of price return

What is price return decomposition?

IMTX News

Last Important Events
Immatics NV

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Immatics NV

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Immatics NV Logo
Immatics NV

Country

Germany

Industry

Biotechnology

Market Cap

1B USD

Dividend Yield

0%

Description

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 188 full-time employees. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Contact

BADEN-WUERTTEMBERG
Tuebingen
Paul Ehrlich-Strasse 15
+4970715397700.0
https://immatics.com/

IPO

-

Employees

188

Officers

CEO, MD, Member of Management Board & Executive Director
Dr. Harpreet Singh Ph.D.
Co-Founder & Chief Innovation Officer
Dr. Toni Weinschenk Ph.D.
Chief Financial Officer
Mr. Arnd Christ MBA
Chief Operations Officer
Mr. Steffen Walter Ph.D.
General Counsel & Secretary
Mr. Edward A. Sturchio J.D.
Chief Development Officer
Dr. Carsten Reinhardt M.D., Ph.D.
Show More
Chief Medical Officer
Mr. Cedrik M. Britten M.D.
Head of Strategy
Mr. Jordan Silverstein
Co-Founder & Member of the Scientific Advisory Board
Dr. Hans-Georg Rammensee Ph.D.
Vice President of SEC Reporting & Accounting
Mr. Ephraim Hofsäß M.Sc.
Show Less

See Also

Discover More
What is the Intrinsic Value of one IMTX stock?

The intrinsic value of one IMTX stock under the Base Case scenario is 5.74 USD.

Is IMTX stock undervalued or overvalued?

Compared to the current market price of 10.15 USD, Immatics NV is Overvalued by 43%.